PVLA
Palvella Therapeutics Inc

260
Mkt Cap
$1.84B
Volume
177,260.00
52W High
$151.18
52W Low
$18.23
PE Ratio
-10.66
PVLA Fundamentals
Price
$134.39
Prev Close
$134.95
Open
$131.51
50D MA
$97.89
Beta
0.98
Avg. Volume
435,761.84
EPS (Annual)
-$7.83
P/B
38.52
Rev/Employee
$0.00
$44.95
Loading...
Loading...
News
all
press releases
Royce & Associates LP Decreases Stock Holdings in Palvella Therapeutics, Inc. $PVLA
Royce & Associates LP reduced its holdings in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 33.6% in the third quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) saw a large growth in short interest in February. As of February 13th, there was short interest totaling 1,674,747 shares, a growth of...
MarketBeat·4d ago
News Placeholder
Elaine Heron Acquires 2,400 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) Director Elaine Heron purchased 2,400 shares of the business's stock in a transaction dated Friday, February 27th. The shares were acquired...
MarketBeat·5d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) Director Elaine Heron acquired 2,400 shares of the firm's stock in a transaction on Friday, February 27th. The stock was purchased at an...
MarketBeat·6d ago
News Placeholder
Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) Director George Jenkins purchased 4,000 shares of the firm's stock in a transaction that occurred on Friday, February 27th. The stock was...
MarketBeat·6d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up After Analyst Upgrade
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up on Analyst Upgrade...
MarketBeat·10d ago
News Placeholder
HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - HC Wainwright boosted their FY2027 earnings estimates for shares of Palvella Therapeutics in a research note issued to investors on Tuesday...
MarketBeat·10d ago
News Placeholder
What is Lifesci Capital's Estimate for PVLA FY2026 Earnings?
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Investment analysts at Lifesci Capital raised their FY2026 earnings estimates for Palvella Therapeutics in a research report issued on...
MarketBeat·10d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho
Mizuho raised their price objective on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an "outperform" rating in a research report on Wednesday...
MarketBeat·11d ago
News Placeholder
BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00
BTIG Research increased their price objective on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a "buy" rating in a research report on Wednesday...
MarketBeat·11d ago
<
1
2
...
>

Latest PVLA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.